Open AccessRenal toxicity with mammalian target of rapamycin inhibitors: A meta-analysis of randomized clinical trials
Author(s) -
Ravi Kumar Paluri,
Guru Sonpavde,
Charity Morgan,
Robin Jacob,
Anastasia Hartzes Mar,
Radhika Gangaraju
Publication year - 2019
Publication title -
oncology reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.637
H-Index - 21
eISSN - 1970-5565
pISSN - 1970-5557
DOI - 10.4081/oncol.2019.455
Subject(s) - medicine , jadad scale , randomized controlled trial , relative risk , meta analysis , clinical trial , acute kidney injury , medline , incidence (geometry) , pharmacology , confidence interval , cochrane library , physics , optics , political science , law
A meta-analysis of randomized clinical trials (RCT) was done to determine the relative risk (RR) of acute kidney injury (AKI) with the use of mammalian target of rapamycin (mTOR) inhibitors. Citations from PubMed/Medline, clinical trials.gov, package inserts and abstracts from major conferences were reviewed to include RCTs comparing arms with or without mTOR inhibitors. The RR of all grade AKI in patients taking mTOR inhibitors compared to patients not on mTOR inhibitors was 1.55 (95% CI: 1.11 to 2.16, P=0.010). There was no significant difference in the risk of high-grade AKI for the two groups (RR=1.29, P=0.118, 95% CI: 0.94 to 1.77). There was no significant difference in the incidence rates for either all grade or high-grade AKI between the two groups. There was no publication bias and the trials were of high quality per Jadad scoring.